Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.

Stengel C, Newman SP, Day JM, Chander SK, Jourdan FL, Leese MP, Ferrandis E, Regis-Lydi S, Potter BV, Reed MJ, Purohit A, Foster PA.

Br J Cancer. 2014 Jul 15;111(2):300-8. doi: 10.1038/bjc.2014.188. Epub 2014 Jun 24.

2.

Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{[(4-cyanophenyl)(4h-1,2,4-triazol-4-yl)amino]methyl}phenylsulfamate: synthesis, SAR, crystal structure, and in vitro and in vivo activities.

Wood PM, Woo LW, Labrosse JR, Thomas MP, Mahon MF, Chander SK, Purohit A, Reed MJ, Potter BV.

ChemMedChem. 2010 Sep 3;5(9):1577-93. doi: 10.1002/cmdc.201000203.

PMID:
20632362
3.

Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.

Woo LW, Jackson T, Putey A, Cozier G, Leonard P, Acharya KR, Chander SK, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2010 Mar 11;53(5):2155-70. doi: 10.1021/jm901705h.

PMID:
20148564
4.

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.

Foster PA, Chander SK, Newman SP, Woo LW, Sutcliffe OB, Bubert C, Zhou D, Chen S, Potter BV, Reed MJ, Purohit A.

Clin Cancer Res. 2008 Oct 15;14(20):6469-77. doi: 10.1158/1078-0432.CCR-08-1027.

5.

The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer.

Parsons MF, Foster PA, Chander SK, Jhalli R, Newman SP, Leese MP, Potter BV, Purohit A, Reed MJ.

Br J Cancer. 2008 Nov 4;99(9):1433-41. doi: 10.1038/sj.bjc.6604707. Epub 2008 Oct 7.

6.

Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, crystal structures, in vitro and in vivo activities.

Bubert C, Woo LW, Sutcliffe OB, Mahon MF, Chander SK, Purohit A, Reed MJ, Potter BV.

ChemMedChem. 2008 Nov;3(11):1708-30. doi: 10.1002/cmdc.200800164.

PMID:
18816537
7.

Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography.

Woo LW, Fischer DS, Sharland CM, Trusselle M, Foster PA, Chander SK, Di Fiore A, Supuran CT, De Simone G, Purohit A, Reed MJ, Potter BV.

Mol Cancer Ther. 2008 Aug;7(8):2435-44. doi: 10.1158/1535-7163.MCT-08-0195.

8.

Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy.

Purohit A, Chander SK, Woo LW, Parsons MF, Jhalli R, Potter BV, Reed MJ.

Anticancer Res. 2008 May-Jun;28(3A):1517-23.

9.

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

Day JM, Foster PA, Tutill HJ, Parsons MF, Newman SP, Chander SK, Allan GM, Lawrence HR, Vicker N, Potter BV, Reed MJ, Purohit A.

Int J Cancer. 2008 May 1;122(9):1931-40. doi: 10.1002/ijc.23350.

10.

Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.

Jackson T, Woo LW, Trusselle MN, Chander SK, Purohit A, Reed MJ, Potter BV.

Org Biomol Chem. 2007 Oct 21;5(20):2940-52.

PMID:
17972413
11.

Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer.

Foster PA, Chander SK, Parsons MF, Newman SP, Woo LW, Potter BV, Reed MJ, Purohit A.

Breast Cancer Res Treat. 2008 Sep;111(1):129-38. Epub 2007 Oct 4.

PMID:
17914670
12.

Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity.

Jackson T, Woo LW, Trusselle MN, Chander SK, Purohit A, Reed MJ, Potter BV.

Org Biomol Chem. 2007 Sep 21;5(18):2940-52. Epub 2007 Aug 7. Erratum in: Org Biomol Chem. 2007 Oct 21;5(20):3368. Corrected and republished in: Org Biomol Chem. 2007 Oct 21;5(20):2940-52.

PMID:
17728860
13.

Dual aromatase-steroid sulfatase inhibitors.

Woo LW, Bubert C, Sutcliffe OB, Smith A, Chander SK, Mahon MF, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2007 Jul 26;50(15):3540-60. Epub 2007 Jun 20.

PMID:
17580845
14.

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol.

Chander SK, Foster PA, Leese MP, Newman SP, Potter BV, Purohit A, Reed MJ.

Br J Cancer. 2007 May 7;96(9):1368-76. Epub 2007 Apr 10.

15.

In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy.

Foster PA, Newman SP, Chander SK, Stengel C, Jhalli R, Woo LL, Potter BV, Reed MJ, Purohit A.

Clin Cancer Res. 2006 Sep 15;12(18):5543-9.

16.

The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.

Purohit A, Tutill HJ, Day JM, Chander SK, Lawrence HR, Allan GM, Fischer DS, Vicker N, Newman SP, Potter BV, Reed MJ.

Mol Cell Endocrinol. 2006 Mar 27;248(1-2):199-203. Epub 2006 Jan 18.

PMID:
16414180
17.

The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells.

Utsumi T, Leese MP, Chander SK, Gaukroger K, Purohit A, Newman SP, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):219-27. Epub 2005 Feb 24.

PMID:
15862969
18.

A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.

Wood PM, Woo LW, Humphreys A, Chander SK, Purohit A, Reed MJ, Potter BV.

J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):123-30. Epub 2005 Feb 5.

PMID:
15862957
19.

Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats.

Ireson CR, Chander SK, Purohit A, Parish DC, Woo LW, Potter BV, Reed MJ.

Br J Cancer. 2004 Oct 4;91(7):1399-404.

20.

The role of steroid sulphatase in regulating the oestrogenicity of oestrogen sulphamates.

Chander SK, Purohit A, Woo LW, Potter BV, Reed MJ.

Biochem Biophys Res Commun. 2004 Sep 10;322(1):217-22.

PMID:
15313194
21.

Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents.

Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BV, Reed MJ.

Br J Cancer. 2004 Feb 23;90(4):932-7.

22.

Steroid sulphatase inhibitors for breast cancer therapy.

Purohit A, Woo LW, Chander SK, Newman SP, Ireson C, Ho Y, Grasso A, Leese MP, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):423-32. Review.

PMID:
14623540
23.

First dual aromatase-steroid sulfatase inhibitors.

Woo LW, Sutcliffe OB, Bubert C, Grasso A, Chander SK, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2003 Jul 17;46(15):3193-6.

PMID:
12852749
24.

Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate.

Raobaikady B, Purohit A, Chander SK, Woo LW, Leese MP, Potter BV, Reed MJ.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):351-8.

PMID:
12711022
25.

Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity.

Fischer DS, Chander SK, Woo LW, Fenton JC, Purohit A, Reed MJ, Potter BV.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):343-9.

PMID:
12711021
26.

Development of a sensitive high-performance liquid chromatography method for the detection of 667 COUMATE in vivo.

Ireson CR, Parish D, Purohit A, Woo LW, Potter BV, Chander SK, Reed MJ.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):337-42.

PMID:
12711020
27.

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor.

An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM.

Clin Exp Metastasis. 1997 Mar;15(2):184-95.

PMID:
9062395
28.

An in vivo model for screening peptidomimetic inhibitors of gelatinase A.

Chander SK, Antoniw P, Beeley NR, Boyce B, Crabbe T, Docherty AJ, Leonard J, Mason B, Millar K, Millican AT, et al.

J Pharm Sci. 1995 Apr;84(4):404-9.

PMID:
7629728
29.

Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumours.

Chander SK, Lansdown AG, Luqmani YA, Gomm JJ, Coope RC, Gould N, Coombes RC.

Br J Cancer. 1994 May;69(5):879-82.

30.

The biological evaluation of novel antioestrogens for the treatment of breast cancer.

Chander SK, Sahota SS, Evans TR, Luqmani YA.

Crit Rev Oncol Hematol. 1993 Dec;15(3):243-69. Review. No abstract available.

PMID:
8142059
31.

Detection of breast cancer-associated estrone sulfatase in breast cancer biopsies and cell lines using polymerase chain reaction.

Evans TR, Rowlands MG, Luqmani YA, Chander SK, Coombes RC.

J Steroid Biochem Mol Biol. 1993 Aug;46(2):195-201.

PMID:
8664167
32.

New endocrine agents for the treatment of breast cancer.

Coombes RC, Jarman M, Dowsett M, Chander SK, Rowlands MG, Di Salle E, Evans TJ.

Recent Results Cancer Res. 1993;127:267-75. Review. No abstract available.

PMID:
8502825
33.

The effect of endocrine therapy on fibroblast growth factor-like activity in nitrosomethylurea-induced rat mammary tumours.

Smith J, Chander SK, Baillie R, Coombes RC.

Eur J Cancer. 1993;29A(15):2125-31.

PMID:
7507688
34.

Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro.

Colston KW, Chander SK, Mackay AG, Coombes RC.

Biochem Pharmacol. 1992 Aug 18;44(4):693-702.

PMID:
1324683
35.

Clinical and biological significance of HSP89 alpha in human breast cancer.

Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA.

Int J Cancer. 1992 Feb 1;50(3):409-15.

PMID:
1735610
36.

Oestrone sulphatase activity in mammary tumours and the liver of N-nitrosomethylurea treated rats.

Evans TR, Chander SK, Rowlands MG, Coombes RC.

Br J Cancer. 1992 Jan;65(1):72-6.

37.

Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

Chander SK, McCague R, Luqmani Y, Newton C, Dowsett M, Jarman M, Coombes RC.

Cancer Res. 1991 Nov 1;51(21):5851-8.

Supplemental Content

Loading ...
Support Center